Keywords
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribers receive full online access to your subscription and archive of back issues up to and including 2002.
Content published before 2002 is available via pay-per-view purchase only.
Subscribe:
Subscribe to Medical ClinicsAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
- Contemporary Epidemiology of Chronic Liver Disease and Cirrhosis.Clin Gastroenterol Hepatol. 2020; 18: 2650-2666
- The global, regional, and national burden of cirrhosis by cause in 195 countries and territories, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017.Lancet Gastroenterol Hepatol. 2020; 5: 245-266
- The prevalence and incidence of NAFLD worldwide: a systematic review and meta-analysis.Lancet Gastroenterol Hepatol. 2022; 7: 851-861
- Epidemiology and natural history of non-alcoholic fatty liver disease.Metabolism. 2016; 65: 1017-1025
- Mortality Outcomes by Fibrosis Stage in Nonalcoholic Fatty Liver Disease: A Systematic Review and Meta-analysis.Clin Gastroenterol Hepatol. 2022; 0https://doi.org/10.1016/J.CGH.2022.04.014
- The long-term pathological evolution of chronic hepatitis C.Hepatology. 1996; 23: 1334-1340
- Histological parameters and alcohol abstinence determine long-term prognosis in patients with alcoholic liver disease.J Hepatol. 2017; 66: 610-618
- Fibrosis Stage-specific Incidence of Hepatocellular Cancer After Hepatitis C Cure With Direct-acting Antivirals: A Systematic Review and Meta-analysis.Clin Gastroenterol Hepatol. 2022; https://doi.org/10.1016/J.CGH.2022.04.013
- Sampling Variability of Liver Fibrosis in Chronic Hepatitis C.Hepatology. 2003; 38: 1449-1457
- Suboptimal reliability of liver biopsy evaluation has implications for randomized clinical trials.J Hepatol. 2020; 73: 1322-1332
- Burden of Disease due to Nonalcoholic Fatty Liver Disease.Gastroenterol Clin North Am. 2020; 49: 1-23
- Systematic review with meta-analysis: prevalence of hepatic steatosis, fibrosis and associated factors in chronic hepatitis B.Aliment Pharmacol Ther. 2021; 54: 1100-1109
- Steatosis and hepatitis C.Gastroenterol Rep (Oxf). 2015; : gov040https://doi.org/10.1093/gastro/gov040
- Steatosis in chronic hepatitis C: Why does it really matter?.Gut. 2006; 55: 123-130
- The impact of steatosis on chronic hepatitis c progression and response to antiviral treatments.Biomedicines. 2021; 9https://doi.org/10.3390/biomedicines9101491
- Mechanisms and significance of liver steatosis in hepatitis C virus infection.World J Gastroenterol : WJG. 2006; 12: 6756
- Metabolic and Genetic Risk Factors Are the Strongest Predictors of Severity of Alcohol-Related Liver Fibrosis.Clin Gastroenterol Hepatol. 2021; https://doi.org/10.1016/j.cgh.2020.11.038
- The fatty liver index: A simple and accurate predictor of hepatic steatosis in the general population.BMC Gastroenterol. 2006; 6https://doi.org/10.1186/1471-230X-6-33
- Hepatic steatosis index: A simple screening tool reflecting nonalcoholic fatty liver disease.Dig Liver Dis. 2010; 42: 503-508
- Prediction of Non-Alcoholic Fatty Liver Disease and Liver Fat Using Metabolic and Genetic Factors.Gastroenterology. 2009; 137: 865-872
- Performance and limitations of steatosis biomarkers in patients with nonalcoholic fatty liver disease.Aliment Pharmacol Ther. 2014; 40: 1209-1222
- Fatty liver hepatitis (steatohepatitis) and obesity: an autopsy study with analysis of risk factors.Hepatology. 1990; 12: 1106-1110
- US-FLI score – Is it possible to predict the steatosis grade with an ultrasonographic score?.Mol Genet Metab. 2021; 132: 204-209
- Ultrasonographic fatty liver indicator, a novel score which rules out NASH and is correlated with metabolic parameters in NAFLD.Liver Int. 2012; 32: 1242-1252
- Noninvasive assessment of hepatic steatosis using a pathologic reference standard: comparison of CT, MRI, and US-based techniques.Ultrasonography. 2021; 41: 344-354
- Noninvasive imaging methods to determine severity of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis.Hepatology. 2016; 64: 2234-2243
- Fatty liver disease in severe obese patients: Diagnostic value of abdominal ultrasound.World J Gastroenterol. 2008; 14: 1415-1418
- Clinical value of liver ultrasound for the diagnosis of nonalcoholic fatty liver disease in overweight and obese patients.Liver Int. 2015; 35: 2139-2146
- Interobserver and intraobserver variability in the sonographic assessment of fatty liver.Am J Roentgenol. 2007; 189: 1449
- The severity of ultrasonographic findings in nonalcoholic fatty liver disease reflects the metabolic syndrome and visceral fat accumulation.Am J Gastroenterol. 2007; 102: 2708-2715
- Quantitative ultrasound imaging of soft biological tissues: a primer for radiologists and medical physicists.Insights Imaging. 2021; 12https://doi.org/10.1186/s13244-021-01071-w
- A novel quantitative ultrasound technique for identifying non-alcoholic steatohepatitis.Liver Int. 2022; 42: 80-91
- Individual patient data meta-analysis of controlled attenuation parameter (CAP) technology for assessing steatosis.J Hepatol. 2017; 66: 1022-1030
- Interobserver reproducibility of the controlled attenuation parameter (CAP) for quantifying liver steatosis.Hepatol Int. 2014; 8: 576-581
- Validity criteria for the diagnosis of fatty liver by M probe-based controlled attenuation parameter.J Hepatol. 2017; 67: 577-584
- Accuracy of FibroScan Controlled Attenuation Parameter and Liver Stiffness Measurement in Assessing Steatosis and Fibrosis in Patients With Nonalcoholic Fatty Liver Disease.Gastroenterology. 2019; 156: 1717-1730
- Accuracy of liver stiffness measurement and controlled attenuation parameter using FibroScan® M/XL probes to diagnose liver fibrosis and steatosis in patients with nonalcoholic fatty liver disease: a multicenter prospective study.J Gastroenterol. 2020; 55: 428-440
- Assessment of hepatic steatosis by controlled attenuation parameter using the M and XL probes: an individual patient data meta-analysis.Lancet Gastroenterol Hepatol. 2021; 6: 185-198
- Optimal threshold of controlled attenuation parameter with MRI-PDFF as the gold standard for the detection of hepatic steatosis.Hepatology. 2018; 67: 1348-1359
- Accuracy of computed tomography for detecting hepatic steatosis in donors for liver transplantation: A meta-analysis.Clin Transpl. 2017; 31: e13013
- Macrovesicular Hepatic Steatosis in Living Liver Donors: Use of CT for Quantitative and Qualitative Assessment1.Radiology. 2006; 239: 105-112
- Macrovesicular Hepatic Steatosis in Living Related Liver Donors: Correlation between CT and Histologic Findings1.Radiology. 2004; 230: 276-280
- Separation of Hepatic Iron and Fat by Dual-Source Dual-Energy Computed Tomography Based on Material Decomposition: An Animal Study.PLoS One. 2014; 9: e110964
- Quantification of liver fat in the presence of iron and iodine: An ex-vivo dual-energy CT study.Invest Radiol. 2011; 46: 351-358
- Assessment of Hepatic Steatosis in Patients Undergoing Liver Resection: Comparison of US, CT, T1-weighted Dual-Echo MR Imaging, and Point-resolved 1H MR Spectroscopy1.Radiology. 2010; 256: 159-168
- Accuracy of MR imaging-estimated proton density fat fraction for classification of dichotomized histologic steatosis grades in nonalcoholic fatty liver disease.Radiology. 2015; 274: 416-425
- Magnetic Resonance Elastography vs Transient Elastography in Detection of Fibrosis and Noninvasive Measurement of Steatosis in Patients With Biopsy-Proven Nonalcoholic Fatty Liver Disease.Gastroenterology. 2017; 152 (e2): 598-607
- Quantitative magnetic resonance imaging of hepatic steatosis: Validation in ex vivo human livers.Hepatology. 2015; 62: 1444-1455
- The Long-Term Pathological Evolution of Chronic Hepatitis C.Hepatology. 1996; 23: 1334-1340
- Pathologic criteria for nonalcoholic steatohepatitis: Interprotocol agreement and ability to predict liver-related mortality.Hepatology. 2011; 53: 1874-1882
- Simple noninvasive fibrosis scoring systems can reliably exclude advanced fibrosis in patients with non-alcoholic fatty liver disease.Gut. 2010; 59: 1265-1269
- Validation of the NAFLD fibrosis score in a Chinese population with low prevalence of advanced fibrosis.Am J Gastroenterol. 2008; 103: 1682-1688
- Development of a simple noninvasive index to predict significant fibrosis in patients with HIV/HCV coinfection.Hepatology. 2006; 43: 1317-1325
- Comparison of laboratory tests, ultrasound, or magnetic resonance elastography to detect fibrosis in patients with nonalcoholic fatty liver disease: A meta-analysis.Hepatology. 2017; 66: 1486-1501
- Age as a Confounding Factor for the Accurate Noninvasive Diagnosis of Advanced NAFLD Fibrosis.Am J Gastroenterol. 2017; 112: 740
- Diagnostic accuracy of noninvasive tests for advanced fibrosis in patients with NAFLD: an individual patient data meta-analysis.Gut. 2022; 71https://doi.org/10.1136/GUTJNL-2021-324243
- Low Accuracy of FIB-4 and NAFLD Fibrosis Scores for Screening for Liver Fibrosis in the Population.Clin Gastroenterol Hepatol. 2021; https://doi.org/10.1016/J.CGH.2021.12.034
- Hyaluronic acid concentration in liver diseases.Clin Exp Med. 2016; 16: 523-528
- Hyaluronic acid, an accurate serum marker for severe hepatic fibrosis in patients with non-alcoholic fatty liver disease.Liver Int. 2005; 25: 779-786
- Diagnostic Value of Serum Procollagen III N-Terminal Peptide for Liver Fibrosis in Infantile Cholestasis.Front Pediatr. 2020; 8https://doi.org/10.3389/fped.2020.00131
- The Neo-Epitope Specific PRO-C3 ELISA Measures True Formation of Type III Collagen Associated with Liver and Muscle Parameters.Am J Transl Res. 2013; 5 (Available at:): 303-315
- Systematic review with meta-analysis: Diagnostic accuracy of pro-c3 for hepatic fibrosis in patients with non-alcoholic fatty liver disease.Biomedicines. 2021; 9https://doi.org/10.3390/biomedicines9121920
- Expression of MMPs and TIMPs in liver fibrosis - a systematic review with special emphasis on anti-fibrotic strategies.J Hepatol. 2007; 46: 955-975
- Tissue inhibitors of metalloproteinase-1 and 2 and obesity related non-alcoholic fatty liver disease: Is there a relationship?.Digestion. 2015; 92: 130-137
- Enhanced liver fibrosis test for the noninvasive diagnosis of fibrosis in patients with NAFLD: A systematic review and meta-analysis.J Hepatol. 2020; 73: 252-262
- The Enhanced Liver Fibrosis (ELF) score: Normal values, influence factors and proposed cut-off values.J Hepatol. 2013; 59: 236-242
- Performance of the Enhanced Liver Fibrosis Test to Estimate Advanced Fibrosis among Patients with Nonalcoholic Fatty Liver Disease.JAMA Netw Open. 2021; 4https://doi.org/10.1001/jamanetworkopen.2021.23923
- Biochemical markers of liver fibrosis in patients with hepatitis C virus infection: a prospective study.Lancet. 2001; 357: 1069-1075
- Diagnostic value of biochemical markers (Fibro Test-FibroSURE) for the prediction of liver fibrosis in patients with non-alcoholic fatty liver disease.BMC Gastroenterol. 2006; 6https://doi.org/10.1186/1471-230X-6-6
- Diagnostic performance of FibroTest, SteatoTest and ActiTest in patients with NAFLD using the SAF score as histological reference.Aliment Pharmacol Ther. 2016; 44: 877-889
- Application of the combined FibroMeter vibration-controlled transient elastography algorithm in Chinese patients with non-alcoholic fatty liver disease.J Gastroenterol Hepatol (Australia). 2017; 32: 1363-1369
- ADAPT: An Algorithm Incorporating PRO-C3 Accurately Identifies Patients With NAFLD and Advanced Fibrosis.Hepatology. 2019; 69: 1075-1086
- Performance of the PRO-C3 collagen neo-epitope biomarker in non-alcoholic fatty liver disease.JHEP Rep. 2019; 1: 188-198
- Refining the Baveno VI elastography criteria for the definition of compensated advanced chronic liver disease.J Hepatol. 2021; 74: 1109-1116
- Real-world evidence on noninvasive tests and associated cut-offs used to assess fibrosis in routine clinical practice.JHEP Rep. 2022; 22: 100596
- Association Between Anthropometric Parameters and Measurements of Liver Stiffness by Transient Elastography.Clin Gastroenterol Hepatol. 2013; 11https://doi.org/10.1016/j.cgh.2012.09.025
- Pitfalls of liver stiffness measurement: A 5-year prospective study of 13,369 examinations.Hepatology. 2010; 51: 828-835
- Liver Stiffness in Nonalcoholic Fatty Liver Disease: A Comparison of Supersonic Shear Imaging, FibroScan, and ARFI With Liver Biopsy a he study of liver diseases t american association for.Hepatology. 2016; 63: 1817-1827
- Comparison of 2-D Shear Wave Elastography and Point Shear Wave Elastography for Assessing Liver Fibrosis.Ultrasound Med Biol. 2021; 47: 408-427
- Magnetic Resonance Imaging More Accurately Classifies Steatosis and Fibrosis in Patients with Nonalcoholic Fatty Liver Disease Than Transient Elastography.Gastroenterology. 2016; 150 (e7): 626-637
- Association Between Obesity and Discordance in Fibrosis Stage Determination by Magnetic Resonance vs Transient Elastography in Patients With Nonalcoholic Liver Disease.Clin Gastroenterol Hepatol. 2018; 16 (e7): 1974-1982
- Advances in noninvasive assessment of hepatic fibrosis.Gut. 2020; 69: 1343-1352
- Direct Comparison of US and MR Elastography for Staging Liver Fibrosis in Patients With Nonalcoholic Fatty Liver Disease.Clin Gastroenterol Hepatol. 2022; 20 (e11): 908-917
- Magnetic Resonance vs Transient Elastography Analysis of Patients With Nonalcoholic Fatty Liver Disease: A Systematic Review and Pooled Analysis of Individual Participants.Clin Gastroenterol Hepatol. 2019; 17 (e8): 630-637
- Fibrosis stage is the strongest predictor for disease-specific mortality in NAFLD after up to 33 years of follow-up.Hepatology. 2015; 61: 1547-1554
- Magnetic resonance elastography for prediction of long-term progression and outcome in chronic liver disease: A retrospective study.Hepatology. 2022; 75: 379-390
- Magnetic resonance elastography increases usefulness and safety of noninvasive screening for esophageal varices.J Gastroenterol Hepatol. 2018; 33: 2022-2028
- Validation of albumin, bilirubin, and platelet criteria for avoiding screening endoscopy in patients with advanced fibrosis.Hepatol Res. 2020; 50: 996-999
- Noninvasive fatty liver markers predict liver disease mortality in the U.S. population.Hepatology. 2016; 63: 1170-1183
- Liver stiffness measurement predicts long-term survival and complications in non-alcoholic fatty liver disease.Liver Int. 2020; 40: 581-589
- Risk Difference of Liver-Related and Cardiovascular Events by Liver Fibrosis Status in Nonalcoholic Fatty Liver Disease.Clin Gastroenterol Hepatol. 2022; 20 (e2): 1171-1173
- Longitudinal association of magnetic resonance elastography-associated liver stiffness with complications and mortality.Aliment Pharmacol Ther. 2022; 55: 292-301
- Hepatic Fibrosis Associates With Multiple Cardiometabolic Disease Risk Factors: The Framingham Heart Study.Hepatology. 2021; 73: 548-559
- Liver Stiffness by Transient Elastography Predicts Liver-Related Complications and Mortality in Patients with Chronic Liver Disease.PLoS One. 2014; 9https://doi.org/10.1371/JOURNAL.PONE.0095776
- Prognostic impact of liver fibrosis and steatosis by transient elastography for cardiovascular and mortality outcomes in individuals with nonalcoholic fatty liver disease and type 2 diabetes: the Rio de Janeiro Cohort Study.Cardiovasc Diabetol. 2021; 20https://doi.org/10.1186/S12933-021-01388-2
- Ability of Noninvasive Scoring Systems to Identify Individuals in the Population at Risk for Severe Liver Disease.Gastroenterology. 2020; 158: 200-214
- Liver fibrosis marker is an independent predictor of cardiovascular morbidity and mortality in the general population.Dig Liver Dis. 2021; 53: 79-85
- The Fibrosis-4 (FIB-4) Index Predicts Cardiovascular Major Adverse Events and Mortality in Patients with Non-alcoholic Fatty Liver Disease.Can J Cardiol. 2022; 0
- The utility of NAFLD fibrosis score for prediction of mortality among patients with nonalcoholic fatty liver disease: A systematic review and meta-analysis of cohort study.Clin Res Hepatol Gastroenterol. 2017; 41: 629-634
- Simple Noninvasive Systems Predict Long-term Outcomes of Patients With Nonalcoholic Fatty Liver Disease.Gastroenterology. 2013; 145 (e4): 782-789
- Enhanced liver fibrosis test can predict clinical outcomes in patients with chronic liver disease.Gut. 2010; 59: 1245-1251
- Expanding consensus in portal hypertension: Report of the Baveno VI Consensus Workshop: Stratifying risk and individualizing care for portal hypertension.J Hepatol. 2015; 63: 743-752
- Baveno VII – Renewing consensus in portal hypertension.J Hepatol. 2022; 76: 959-974
- When the spleen gets tough, the varices get going.Gastroenterology. 2013; 144: 19-22
- The usefulness of noninvasive liver stiffness measurements in predicting clinically significant portal hypertension in cirrhotic patients: Korean data.Clin Mol Hepatol. 2013; 19: 370
- The Value of Liver and Spleen Stiffness for Evaluation of Portal Hypertension in Compensated Cirrhosis.Hepatol Commun. 2022; 6: 950-964
- EASL Clinical Practice Guidelines on noninvasive tests for evaluation of liver disease severity and prognosis – 2021 update.J Hepatol. 2021; 75: 659-689
- Performance of Baveno VI and Expanded Baveno VI Criteria for Excluding High-Risk Varices in Patients With Chronic Liver Diseases: A Systematic Review and Meta-analysis.Clin Gastroenterol Hepatol. 2019; 17 (e11): 1744-1755
- Baveno criteria safely identify patients with compensated advanced chronic liver disease who can avoid variceal screening endoscopy: A diagnostic test accuracy meta-analysis.Front Physiol. 2019; 10: 1028
- A Meta-analysis for the Diagnostic Performance of Transient Elastography for Clinically Significant Portal Hypertension.Ultrasound Med Biol. 2017; 43: 59-68
- Validation of the New Diagnostic Criteria for Clinically Significant Portal Hypertension by Platelets and Elastography.Dig Dis Sci. 2022; 67: 3327
- Clinical Care Pathway for the Risk Stratification and Management of Patients With Nonalcoholic Fatty Liver Disease.Gastroenterology. 2021; 161: 1657-1669
- American Association of Clinical Endocrinology Clinical Practice Guideline for the Diagnosis and Management of Nonalcoholic Fatty Liver Disease in Primary Care and Endocrinology Clinical Settings: Co-Sponsored by the American Association for the Study of Liver Diseases (AASLD).Endocr Pract. 2022; 28: 528-562
- AGILE 3+ Score for Assessing Hepatic Fibrosis in Patients with Non-Alcoholic Fatty Liver Disease (NAFLD) – Validation in an Indian Cohort.J Clin Exp Hepatol. 2022; 12: S65
- AGILE 3+ Score for the Diagnosis of Advanced Fibrosis and for Predicting Liver-related Events in NAFLD.Clin Gastroenterol Hepatol. 2022; https://doi.org/10.1016/J.CGH.2022.06.013
- FibroScan-AST (FAST) score for the noninvasive identification of patients with non-alcoholic steatohepatitis with significant activity and fibrosis: a prospective derivation and global validation study.Lancet Gastroenterol Hepatol. 2020; 5: 362
- Validation of the accuracy of the FASTTM score for detecting patients with at-risk nonalcoholic steatohepatitis (NASH) in a North American cohort and comparison to other noninvasive algorithms.PLoS One. 2022; 17: e0266859
- MRI-based (MAST) score accurately identifies patients with NASH and significant fibrosis.J Hepatol. 2022; 76: 781-787
- MRE combined with FIB-4 (MEFIB) Index in detection of candidates for pharmacologic treatment of NASH related fibrosis.Gut. 2021; 70: 1946
- Liver Stiffness on Magnetic Resonance Elastography and the MEFIB Index and Liver-Related Outcomes in Nonalcoholic Fatty Liver Disease: A Systematic Review and Meta-Analysis of Individual Participants.Gastroenterology. 2022; https://doi.org/10.1053/J.GASTRO.2022.06.073
- Head to head comparison between MEFIB, MAST, and FAST for detecting stage 2 fibrosis or higher among patients with NAFLD.J Hepatol. 2022; 13https://doi.org/10.1016/J.JHEP.2022.07.020
- Combining FIB-4 and liver stiffness into the FIB-5, a single model that accurately predicts complications of portal hypertension.Am J Gastroenterol. 2022; https://doi.org/10.14309/AJG.0000000000001906
- Update on Prevention, Diagnosis, and Treatment and of Chronic Hepatitis B: AASLD 2018 Hepatitis B Guidance.Hepatology. 2018; 67: 1560
- Hepatitis C Guidance 2019 Update: American Association for the Study of Liver Diseases–Infectious Diseases Society of America Recommendations for Testing, Managing, and Treating Hepatitis C Virus Infection.Hepatology. 2020; 71: 686-721
- EASL recommendations on treatment of hepatitis C: Final update of the series.J Hepatol. 2020; 73: 1170-1218
- EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection.J Hepatol. 2017; 67: 370-398
- HCC surveillance after SVR in patients with F3/F4 fibrosis.J Hepatol. 2021; 74: 458-465
- Clinical outcomes in patients with chronic hepatitis C after direct-acting antiviral treatment: a prospective cohort study.The Lancet. 2019; 393: 1453-1464
- Incidence of liver- and non-liver-related outcomes in patients with HCV-cirrhosis after SVR.J Hepatol. 2022; 76: 302-310
- A morphometric and immunohistochemical study to assess the benefit of a sustained virological response in hepatitis C virus patients with cirrhosis.Hepatology. 2012; 56: 532-543
- Noninvasive Risk Stratification After HCV Eradication in Patients With Advanced Chronic Liver Disease.Hepatology. 2021; 73: 1275-1289
- Noninvasive tests for clinically significant portal hypertension after HCV cure.J Hepatol. 2022; 0https://doi.org/10.1016/J.JHEP.2022.08.025
- Increased risk of mortality by fibrosis stage in nonalcoholic fatty liver disease: Systematic review and meta-analysis.Hepatology. 2017; 65: 1557-1565
- Expert Panel Review to Compare FDA and EMA Guidance on Drug Development and Endpoints in Nonalcoholic Steatohepatitis.Gastroenterology. 2022; 162: 680-688
- Noncirrhotic Nonalcoholic Steatohepatitis With Liver Fibrosis: Developing Drugs for Treatment | FDA.(Available at:) (Accessed August 21, 2022)
- Draft reflection paper on regulatory requirements for the development of medicinal products for chronic non-infectious liver diseases (PBC, PSC, NASH) | European Medicines Agency.(Available at:) (Accessed August 21, 2022)
- Randomised clinical trial: Pemafibrate, a novel selective peroxisome proliferator-activated receptor α modulator (SPPARMα), versus placebo in patients with non-alcoholic fatty liver disease.Aliment Pharmacol Ther. 2021; 54: 1263
- Randomised clinical trial: semaglutide versus placebo reduced liver steatosis but not liver stiffness in subjects with non-alcoholic fatty liver disease assessed by magnetic resonance imaging.Aliment Pharmacol Ther. 2021; 54: 1150
- Clinical utility of 30% relative decline in MRI-PDFF in predicting fibrosis regression in non-alcoholic fatty liver disease.Gut. 2022; 71: 983-990
- Change in MRI-PDFF and Histologic Response in Patients With Nonalcoholic Steatohepatitis: A Systematic Review and Meta-Analysis.Clin Gastroenterol Hepatol. 2021; 19 (e5): 2274-2283
Article info
Publication history
Published online: February 20, 2023
Identification
Copyright
© 2023 Elsevier Inc. All rights reserved.